Clinical Trial Update: Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 1/Phase 2 study combining Radium-223 with Lutetium-177 PSMA-I&T for metastatic castration-resistant prostate cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-I&T (lutetium-177-PSMA-I&T)
• Radium-223 (radium-223 dichloride)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Metastatic Castration-resistant Prostate Cancer, MCRPC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING